Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer-Reference-Cited by-同舟云学术

Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer

Published:2022-02 Issue:02 Volume:82 Page:215-225
ISSN:0016-5751
Container-title:Geburtshilfe und Frauenheilkunde
language:de
Short-container-title:Geburtshilfe Frauenheilkd

Author:

Lüftner Diana¹,Schütz Florian²,Stickeler Elmar³,Fasching Peter A.⁴,Janni Wolfgang⁵,Kolberg-Liedtke Cornelia⁶⁷⁸,Kolberg Hans-Christian⁹,Thomssen Christoph¹⁰,Müller Volkmar¹¹,Fehm Tanja N.¹²,Belleville Erik¹³,Bader Simon⁴,Untch Michael¹⁴,Welslau Manfred¹⁵,Thill Marc¹⁶,Tesch Hans¹⁷,Ditsch Nina¹⁸,Lux Michael P.¹⁹,Wöckel Achim²⁰,Aktas Bahriye²¹,Schneeweiss Andreas²²,Würstlein Rachel²³,Hartkopf Andreas D.²⁴

Affiliation:

1. Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, University Medicine Berlin, Berlin, Germany

2. Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany

3. Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany

4. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

5. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany

6. Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany

7. palleos healthcare, Wiesbaden, Germany

8. Phaon Scientific, Wiesbaden, Germany

9. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany

10. Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany

11. Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

12. Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany

13. ClinSol GmbH & Co KG, Würzburg, Germany

14. Clinic for Gynecology and Obstetrics, Breast Cancer Center, Genecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany

15. Onkologie Aschaffenburg, Aschaffenburg, Germany

16. Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt am Main, Germany

17. Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany

18. Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany

19. Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany

20. Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany

21. Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Leipzig, Leipzig, Germany

22. National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

23. Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany

24. Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany

Abstract

AbstractDespite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumab-emtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials.

Publisher

Georg Thieme Verlag KG

Subject

Maternity and Midwifery,Obstetrics and Gynecology

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-1724-9569.pdf

Reference59 articles.

1. Third annual William L. McGuire Memorial Lecture. “Studies on the estrogen receptor in breast cancer” – 20 years as a target for the treatment and prevention of cancer;V C Jordan;Breast Cancer Res Treat,1995

2. LBA17_PR – Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB);G N Hortobagyi;Ann Oncol,2021

3. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival;D J Slamon;Ann Oncol,2021

4. Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib;D Tripathy;Cancer Res,2021

5. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3;M Cristofanilli;J Clin Oncol,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update Mammakarzinom 2022 Teil 6 – Brustkrebs in fortgeschrittenen Krankheitsstadien;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2023-06

2. Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer;Geburtshilfe und Frauenheilkunde;2023-03

3. Update Mammakarzinom 2022 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2022-12

4. Update Mammakarzinom 2022 Teil 1 – Brustkrebs in frühen Krankheitsstadien;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2022-09

5. Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer;Geburtshilfe und Frauenheilkunde;2022-06